US4994373A
(en)
|
1983-01-27 |
1991-02-19 |
Enzo Biochem, Inc. |
Method and structures employing chemically-labelled polynucleotide probes
|
US4599230A
(en)
*
|
1984-03-09 |
1986-07-08 |
Scripps Clinic And Research Foundation |
Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
|
US4599231A
(en)
*
|
1984-03-09 |
1986-07-08 |
Scripps Clinic And Research Foundation |
Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
|
AU579148B2
(en)
*
|
1984-03-09 |
1988-11-17 |
Scripps Clinic And Research Foundation |
Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
|
US5998578A
(en)
*
|
1984-05-18 |
1999-12-07 |
New England Medical Center Hospitals, Inc. |
Biologically active fragments of IL-1β
|
CA1255586A
(en)
*
|
1984-07-24 |
1989-06-13 |
Hendrik M. Geysen |
Method of determining mimotopes
|
AU592311B2
(en)
*
|
1984-07-24 |
1990-01-11 |
Coselco Mimotopes Pty Ltd |
Method for determining mimotopes
|
US4798787A
(en)
*
|
1984-09-19 |
1989-01-17 |
Cetus Corporation |
Peptide antibodies and their use in detecting oncogene products
|
US4762706A
(en)
*
|
1984-10-17 |
1988-08-09 |
Cetus Corporation |
Peptide antibodies and their use in detecting oncogene products
|
WO1986006487A1
(en)
|
1985-04-22 |
1986-11-06 |
Commonwealth Serum Laboratories Commission |
Method for determining mimotopes
|
NZ215865A
(en)
*
|
1985-04-22 |
1988-10-28 |
Commw Serum Lab Commission |
Method of determining the active site of a receptor-binding analogue
|
AU592560B2
(en)
*
|
1985-04-22 |
1990-01-18 |
Coselco Mimotopes Pty Ltd |
Improved method for determining mimotopes
|
US5866363A
(en)
|
1985-08-28 |
1999-02-02 |
Pieczenik; George |
Method and means for sorting and identifying biological information
|
ATE165363T1
(de)
*
|
1985-08-28 |
1998-05-15 |
George Pieczenik |
Verfahren und mittel zur sortierung und bestimmung biologischer informationen
|
US5075211A
(en)
*
|
1986-03-26 |
1991-12-24 |
Genetic Systems Corporation |
Synthetic antigen for the detection of AIDS-related disease
|
IE64356B1
(en)
*
|
1986-07-28 |
1995-07-26 |
Bioscience Int Inc |
Diagnosis severity prediction and monitoring of disease by immunoassay of free activation peptides of pancreatic zymogens
|
GB8709274D0
(en)
*
|
1987-04-16 |
1987-05-20 |
Wellcome Found |
Peptides
|
US4981782A
(en)
*
|
1987-05-14 |
1991-01-01 |
Sri International |
Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
|
US5780038A
(en)
*
|
1987-11-16 |
1998-07-14 |
Roche Diagnostic Systems, Inc. |
HIV-2 envelope polypeptides
|
US5200320A
(en)
*
|
1987-12-07 |
1993-04-06 |
National Jewish Center For Immunology And Respiratory Medicine |
Method for identifying useful polypeptide vaccines
|
GB8810400D0
(en)
|
1988-05-03 |
1988-06-08 |
Southern E |
Analysing polynucleotide sequences
|
US5700637A
(en)
*
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
US7811751B2
(en)
|
1988-05-03 |
2010-10-12 |
Oxford Gene Technology Limited |
Analysing polynucleotide sequences
|
US6054270A
(en)
*
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
FR2631451A1
(fr)
*
|
1988-05-13 |
1989-11-17 |
Inst Nat Sante Rech Med |
Procede de caracterisation de l'epitope intervenant dans une reaction antigene anticorps, kit ou necessaire pour la mise en oeuvre du procede
|
US5003043A
(en)
*
|
1988-05-25 |
1991-03-26 |
Triton Biosciences Inc. |
Peptides representing epitopic sites for the major HTLV-I envelope protein, antibodies thereto, and uses thereof
|
DE3911794A1
(de)
*
|
1989-04-11 |
1990-10-18 |
Thomae Gmbh Dr K |
Monoklonale antikoerper gegen rekombinaten humanen gewebeplasminogenaktivator mit definierter epitopspezifitaet, deren herstellung und deren verwendung
|
US5243030A
(en)
*
|
1989-05-24 |
1993-09-07 |
Sri International |
Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection
|
US5136019A
(en)
*
|
1989-05-24 |
1992-08-04 |
Sri International |
Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
|
US5286789A
(en)
*
|
1989-05-26 |
1994-02-15 |
Applied Immune Sciences, Inc. |
Solid phase multiple peptide synthesis
|
US5143854A
(en)
*
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
US5547839A
(en)
|
1989-06-07 |
1996-08-20 |
Affymax Technologies N.V. |
Sequencing of surface immobilized polymers utilizing microflourescence detection
|
US5744101A
(en)
*
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
EP0486526B2
(de)
|
1989-08-07 |
2001-03-07 |
Peptech Limited |
Bindeligande für tumornekrosisfaktor
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
US20030225254A1
(en)
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
DE3935572A1
(de)
*
|
1989-10-25 |
1991-05-02 |
Biotechnolog Forschung Gmbh |
Verfahren zur peptidsynthese und traeger dafuer
|
FI910245A
(fi)
*
|
1990-01-24 |
1991-07-25 |
United Biomedical Inc |
Syntetiska peptidkompositioner med immunoreaktivitet mot htlv-antikroppar.
|
US5366862A
(en)
*
|
1990-02-14 |
1994-11-22 |
Receptor Laboratories, Inc. |
Method for generating and screening useful peptides
|
EP0445801A3
(en)
*
|
1990-03-08 |
1992-07-01 |
Kuraray Co., Ltd. |
Peptide and its use
|
US5650489A
(en)
*
|
1990-07-02 |
1997-07-22 |
The Arizona Board Of Regents |
Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
|
CA2090860C
(en)
*
|
1990-11-21 |
2003-09-16 |
Richard A. Houghten |
Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
|
US6197529B1
(en)
|
1990-11-21 |
2001-03-06 |
Torrey Pines Institute For Molecular Studies |
Linear substituted oligoalkyleneimine libraries
|
ES2155822T3
(es)
*
|
1990-12-06 |
2001-06-01 |
Affymetrix Inc |
Compuestos y su utilizacion en una estrategia de sintesis binaria.
|
WO1993004079A1
(en)
*
|
1991-08-21 |
1993-03-04 |
Receptor Laboratories, Inc. |
Method for generating and screening useful peptides
|
AU2547592A
(en)
*
|
1991-08-23 |
1993-03-16 |
Isis Pharmaceuticals, Inc. |
Synthetic unrandomization of oligomer fragments
|
US5747253A
(en)
*
|
1991-08-23 |
1998-05-05 |
Isis Pharmaceuticals, Inc. |
Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
|
WO1993006121A1
(en)
*
|
1991-09-18 |
1993-04-01 |
Affymax Technologies N.V. |
Method of synthesizing diverse collections of oligomers
|
US5811246A
(en)
*
|
1991-12-17 |
1998-09-22 |
The Research Foundation Of State University Of New York |
Process for immobilization onto the surfaces of ELISA plates of a compound carrier complex and for immunization
|
JP3151054B2
(ja)
*
|
1992-06-25 |
2001-04-03 |
協和醗酵工業株式会社 |
抗dcc遺伝子産物モノクローナル抗体
|
EP0582450A3
(de)
*
|
1992-08-03 |
1994-11-23 |
Rohto Pharma |
Antikörper gegen Oxytocin-Rezeptor und deren Herstellung.
|
US5846731A
(en)
*
|
1993-06-17 |
1998-12-08 |
Torry Pines Institute For Molecular Studies |
Peralkylated oligopeptide mixtures
|
US5480971A
(en)
*
|
1993-06-17 |
1996-01-02 |
Houghten Pharmaceuticals, Inc. |
Peralkylated oligopeptide mixtures
|
US6448379B1
(en)
*
|
1993-09-14 |
2002-09-10 |
Chiron Corporation |
IL8 inhibitors
|
US5922545A
(en)
*
|
1993-10-29 |
1999-07-13 |
Affymax Technologies N.V. |
In vitro peptide and antibody display libraries
|
US6287787B1
(en)
|
1993-11-24 |
2001-09-11 |
Torrey Pines Institute For Molecular Studies |
Dimeric oligopeptide mixture sets
|
US5559023A
(en)
*
|
1994-02-10 |
1996-09-24 |
Cancer Institute |
Tumor suppressor gene
|
US5834245A
(en)
*
|
1994-07-29 |
1998-11-10 |
Cancer Institute |
PRLTS proteins and DNA's encoding the same
|
ATE209660T1
(de)
|
1994-08-12 |
2001-12-15 |
Myriad Genetics Inc |
17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
|
NZ291621A
(en)
|
1994-08-12 |
1998-09-24 |
Myriad Genetics Inc |
Isolation and detection of human breast cancer and ovarian cancer predisposing gene, brca1
|
US5582997A
(en)
*
|
1994-08-24 |
1996-12-10 |
Torrey Pines Institute For Molecular Studies |
Lysine/leucine polypeptides, mixture sets and libraries thereof
|
US5645996A
(en)
*
|
1994-08-24 |
1997-07-08 |
Torrey Pines Institute For Molecular Studies |
Melittin-related polypeptides, mixture sets and libraries thereof
|
US5837492A
(en)
|
1995-12-18 |
1998-11-17 |
Myriad Genetics, Inc. |
Chromosome 13-linked breast cancer susceptibility gene
|
US6121489A
(en)
*
|
1996-03-05 |
2000-09-19 |
Trega Biosciences, Inc. |
Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
|
EP1464703A3
(de)
|
1996-03-07 |
2004-10-13 |
Eisai Co., Ltd. |
Adhäsionsmolekül Occludin vom Hund
|
JP3894381B2
(ja)
*
|
1996-04-10 |
2007-03-22 |
株式会社ペプチド研究所 |
抗Glu▲17▼−オステオカルシン抗体
|
EP0920505B1
(de)
|
1996-08-16 |
2008-06-04 |
Schering Corporation |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
US6610839B1
(en)
|
1997-08-14 |
2003-08-26 |
Geron Corporation |
Promoter for telomerase reverse transcriptase
|
US6475789B1
(en)
|
1996-10-01 |
2002-11-05 |
University Technology Corporation |
Human telomerase catalytic subunit: diagnostic and therapeutic methods
|
US6093809A
(en)
*
|
1996-10-01 |
2000-07-25 |
University Technology Corporation |
Telomerase
|
US6261836B1
(en)
|
1996-10-01 |
2001-07-17 |
Geron Corporation |
Telomerase
|
US7585622B1
(en)
|
1996-10-01 |
2009-09-08 |
Geron Corporation |
Increasing the proliferative capacity of cells using telomerase reverse transcriptase
|
US6808880B2
(en)
|
1996-10-01 |
2004-10-26 |
Geron Corporation |
Method for detecting polynucleotides encoding telomerase
|
CA2266752A1
(en)
|
1996-10-01 |
1998-04-09 |
Geron Corporation |
Telomerase reverse transcriptase
|
US5919638A
(en)
*
|
1996-10-08 |
1999-07-06 |
Abbott Laboratories |
Reagents and methods useful for detecting prostate tumors
|
GB9907461D0
(en)
|
1999-03-31 |
1999-05-26 |
King S College London |
Neurite regeneration
|
US20050202499A1
(en)
|
1996-10-31 |
2005-09-15 |
Billing-Medel Patricia A. |
Reagents and methods useful for detecting diseases of the breast
|
US6441172B1
(en)
|
1996-11-07 |
2002-08-27 |
Torrey Pines Institute For Molecular Studies |
Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
|
AU5697098A
(en)
|
1996-12-13 |
1998-07-03 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
JP3618497B2
(ja)
*
|
1996-12-27 |
2005-02-09 |
富士通株式会社 |
タンパク質の抗原決定基予測方法及びシステム
|
US5981201A
(en)
|
1997-01-08 |
1999-11-09 |
Beth Israel Deaconess Medical Center |
Methods of detection and treatment of breast cancer
|
US6262242B1
(en)
|
1997-01-30 |
2001-07-17 |
Board Of Regents, The University Of Texas System |
Tumor suppressor designated TS10Q23.3
|
US6482795B1
(en)
|
1997-01-30 |
2002-11-19 |
Myriad Genetics, Inc. |
Tumor suppressor designated TS10q23.3
|
US7413864B2
(en)
|
1997-04-18 |
2008-08-19 |
Geron Corporation |
Treating cancer using a telomerase vaccine
|
US7622549B2
(en)
|
1997-04-18 |
2009-11-24 |
Geron Corporation |
Human telomerase reverse transcriptase polypeptides
|
ATE397018T1
(de)
|
1997-07-09 |
2008-06-15 |
Schering Corp |
Isolierte dentritische zell membran protein gene
|
PE20000183A1
(es)
|
1997-07-25 |
2000-03-11 |
Schering Corp |
Citoquinas de mamiferos y reactivos relacionados
|
JP2001512017A
(ja)
|
1997-08-01 |
2001-08-21 |
シェーリング コーポレイション |
哺乳動物細胞膜タンパク質;関連試薬
|
CA2382376A1
(en)
|
1997-09-17 |
1999-03-25 |
Genentech, Inc. |
Novel polypeptides and nucleic acids encoding pro287 which are useful for treating disorders of the pancreas
|
US7378244B2
(en)
|
1997-10-01 |
2008-05-27 |
Geron Corporation |
Telomerase promoters sequences for screening telomerase modulators
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
NZ504548A
(en)
|
1997-12-03 |
2003-06-30 |
Genentech Inc |
Polypeptides and nucleic acids encoding human chordin
|
US6780609B1
(en)
|
1998-10-23 |
2004-08-24 |
Genome Therapeutics Corporation |
High bone mass gene of 1.1q13.3
|
WO1999046598A1
(en)
|
1998-03-10 |
1999-09-16 |
The Regents Of The University Of California |
Methods and tools for identifying compounds which modulate atherosclerosis by impacting ldl-proteoglycan binding
|
NZ525914A
(en)
|
1998-03-10 |
2004-03-26 |
Genentech Inc |
Novel polypeptides and nucleic acids encoding the same
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
PT1076703E
(pt)
|
1998-05-15 |
2007-10-10 |
Genentech Inc |
''utilizações terapêuticas de polipéptido homólogos de il-17''
|
EP1865061A3
(de)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
EP3112468A1
(de)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17-homologe polypeptide und therapeutische verwendung davon
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6322976B1
(en)
|
1998-05-28 |
2001-11-27 |
Medical Research Council |
Compositions and methods of disease diagnosis and therapy
|
US7060431B2
(en)
*
|
1998-06-24 |
2006-06-13 |
Illumina, Inc. |
Method of making and decoding of array sensors with microspheres
|
AU4834999A
(en)
|
1998-06-26 |
2000-01-17 |
Incyte Pharmaceuticals, Inc. |
Human signal peptide-containing proteins
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
EP2314696A1
(de)
|
1998-09-21 |
2011-04-27 |
Schering Corporation |
Therapeutische Verwendungen von humanem Interleukin-B50 Antagonist.
|
EP0997476A3
(de)
|
1998-09-25 |
2000-07-19 |
Schering-Plough |
Antikörper gegen ein Antigen auf Langerhans Zellen in Säugetieren und deren Verwendungen
|
CA2450402A1
(en)
|
1998-12-22 |
2000-06-29 |
Genentech, Inc. |
Methods and compositions for inhibiting cancer cell growth comprising pro224
|
US6429027B1
(en)
*
|
1998-12-28 |
2002-08-06 |
Illumina, Inc. |
Composite arrays utilizing microspheres
|
US7612020B2
(en)
|
1998-12-28 |
2009-11-03 |
Illumina, Inc. |
Composite arrays utilizing microspheres with a hybridization chamber
|
DE60041393D1
(de)
|
1999-03-11 |
2009-03-05 |
Schering Corp |
Cytokine aus säugetieren, verwandte reagenzien und verfahren
|
NZ527293A
(en)
|
1999-03-23 |
2005-01-28 |
Genentech Inc |
Secreted polypeptides and nucleic acids encoding the same isolated from humans
|
ATE315787T1
(de)
|
1999-05-14 |
2006-02-15 |
Univ Mcgill |
Methoden zur identifizierung von modulatoren wechselwirkender proteine
|
EP1684077A1
(de)
*
|
1999-05-14 |
2006-07-26 |
McGill University |
Verfahren zur Identifizierung von Modulatoren wechselwirkender Proteine
|
EP1978029A3
(de)
|
1999-06-15 |
2008-10-15 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
DK1200592T3
(da)
|
1999-07-30 |
2009-12-07 |
Schering Corp |
Mammalske cytokiner og relaterede reagenser
|
AU6794700A
(en)
|
1999-08-20 |
2001-03-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression
|
EP1905832A3
(de)
|
1999-09-09 |
2009-09-09 |
Schering Corporation |
Säuger Interleukin-12 P40 und Interleukin B30, Antikörper, Verwendungen in pharmazeutischen Zusammenstellungen
|
US20030235594A1
(en)
*
|
1999-09-14 |
2003-12-25 |
Antigen Express, Inc. |
Ii-Key/antigenic epitope hybrid peptide vaccines
|
US6432409B1
(en)
*
|
1999-09-14 |
2002-08-13 |
Antigen Express, Inc. |
Hybrid peptides modulate the immune response
|
US9289487B2
(en)
*
|
1999-09-14 |
2016-03-22 |
Antigen Express, Inc. |
II-key/antigenic epitope hybrid peptide vaccines
|
CA2389317A1
(en)
|
1999-10-20 |
2001-04-26 |
Frederic J. De Sauvage |
Modulation of t cell differentiation for the treatment of t helper cell mediated diseases
|
DE19953775A1
(de)
|
1999-11-09 |
2001-05-10 |
Bayer Ag |
Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
|
AU2055401A
(en)
|
1999-12-01 |
2001-06-12 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
EP1897947B1
(de)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17-homologe Polypeptide und ihre therapeutische Verwendung
|
ATE424457T1
(de)
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
US7582420B2
(en)
*
|
2001-07-12 |
2009-09-01 |
Illumina, Inc. |
Multiplex nucleic acid reactions
|
EP1125905A1
(de)
*
|
2000-02-16 |
2001-08-22 |
Pepscan Systems B.V. |
Synthese von Segmenten
|
WO2004043361A2
(en)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
EP1276756A4
(de)
|
2000-04-12 |
2004-06-09 |
Human Genome Sciences Inc |
Albumin fusionsproteine
|
EP1272208B1
(de)
|
2000-04-12 |
2011-10-05 |
VIB vzw |
Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
|
CA2304494A1
(en)
|
2000-04-20 |
2001-10-20 |
Philippe Seguela |
A novel heteromultimeric ion channel receptor and uses thereof
|
ATE321069T1
(de)
|
2000-05-12 |
2006-04-15 |
Vlaams Interuniv Inst Biotech |
Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
|
US20020110843A1
(en)
*
|
2000-05-12 |
2002-08-15 |
Dumas David P. |
Compositions and methods for epitope mapping
|
US6573370B1
(en)
|
2000-05-19 |
2003-06-03 |
Regents Of The University Of Michigan |
PON3 and uses thereof
|
US6656700B2
(en)
|
2000-05-26 |
2003-12-02 |
Amersham Plc |
Isoforms of human pregnancy-associated protein-E
|
US6686188B2
(en)
*
|
2000-05-26 |
2004-02-03 |
Amersham Plc |
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
|
EP1294391B1
(de)
|
2000-06-09 |
2012-08-15 |
Bristol-Myers Squibb Company |
Wirkstoffkombination zur verhinderung der transplantatabstossung
|
WO2001098323A2
(en)
|
2000-06-16 |
2001-12-27 |
Incyte Genomics, Inc. |
G-protein coupled receptors
|
EP2168980A1
(de)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
EP2792747A1
(de)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
GB0020498D0
(en)
|
2000-08-18 |
2000-10-11 |
Sterix Ltd |
Compound
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(de)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
|
JP4624644B2
(ja)
|
2000-09-25 |
2011-02-02 |
ピコリター インコーポレイテッド |
複数のリザブワーからの流体の音響出射
|
US20020123474A1
(en)
*
|
2000-10-04 |
2002-09-05 |
Shannon Mark E. |
Human GTP-Rho binding protein2
|
EP1197755A1
(de)
*
|
2000-10-11 |
2002-04-17 |
Pepscan Systems B.V. |
Bestimmung von Protein-Bindungsstellen
|
CA2464121C
(en)
|
2000-10-20 |
2013-08-13 |
Como Biotech Aps |
Pregnancy-associated plasma protein-a2 (papp-a2)
|
US7060442B2
(en)
|
2000-10-30 |
2006-06-13 |
Regents Of The University Of Michigan |
Modulators on Nod2 signaling
|
US7608704B2
(en)
|
2000-11-08 |
2009-10-27 |
Incyte Corporation |
Secreted proteins
|
AU2002256990A1
(en)
*
|
2001-02-07 |
2002-09-24 |
The Burnham Institute |
Apoptosis modulator bcl-b and methods for making and using same
|
AU2002250032B2
(en)
|
2001-02-09 |
2008-06-05 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor (CCR5) HDGNR10
|
US20020160527A1
(en)
|
2001-02-26 |
2002-10-31 |
3M Innovative Properties Company |
Combinatorial library comprising pouches as packages for library members and method therefor
|
US6849449B2
(en)
|
2001-03-01 |
2005-02-01 |
Regents Of The University Of Michigan |
Orphanin FQ receptor nucleic acids
|
US7514263B2
(en)
|
2001-04-02 |
2009-04-07 |
3M Innovative Properties Company |
Continuous process for the production of combinatorial libraries of materials
|
US20020193295A1
(en)
*
|
2001-05-04 |
2002-12-19 |
Emanuel Calenoff |
Immunogenic peptides and uses thereof
|
RS51635B
(sr)
*
|
2001-04-26 |
2011-08-31 |
Biogen Idec Ma Inc. |
Antitela koja blokiraju cripto i njihova upotreba
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
KR100607612B1
(ko)
|
2001-06-20 |
2006-08-02 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
AU2003904154A0
(en)
|
2003-08-07 |
2003-08-21 |
Bionomics Limited |
Mutations in ion channels
|
WO2003008574A1
(en)
|
2001-07-18 |
2003-01-30 |
Bionomics Limited |
Mutations in ion channels
|
GB0118155D0
(en)
|
2001-07-25 |
2001-09-19 |
Lorantis Ltd |
Superantigen
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
US20140248273A1
(en)
|
2001-09-08 |
2014-09-04 |
Jos van Strijp |
Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)
|
WO2003099318A2
(en)
|
2002-05-29 |
2003-12-04 |
DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung |
Pancreas-specific proteins
|
EP2153843B1
(de)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
NZ554534A
(en)
|
2001-09-27 |
2008-10-31 |
Bionomics Ltd |
DNA sequences for human angiogenesis genes
|
US7354898B2
(en)
|
2001-10-02 |
2008-04-08 |
University Of Chicago |
Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
|
EP1440083B1
(de)
|
2001-10-25 |
2013-01-02 |
Medical Research Council |
Moleküle
|
DK1439863T3
(da)
|
2001-10-29 |
2011-03-14 |
Boehringer Ingelheim Int |
MNK-kinase-homologe proteiner, som er involveret i reguleringen af energihomeostase og organelmetabolisme
|
US7462472B2
(en)
|
2001-11-02 |
2008-12-09 |
The University Of Chicago |
Methods and compositions relating to anthrax pathogenesis
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2003205615B2
(en)
|
2002-01-10 |
2008-09-25 |
Universiteit Gent |
A novel splice variant of MyD88 and uses thereof
|
US6861523B2
(en)
|
2002-02-08 |
2005-03-01 |
Torrey Pines Institute For Molecular Studies |
1,3,5- trisubstituted-1,3,5-triazine-2,4,6-trione compounds and libraries
|
AU2003222225A1
(en)
|
2002-02-20 |
2003-09-09 |
Incyte Corporation |
Receptors and membrane-associated proteins
|
EP2388265A1
(de)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
|
EP1571968A4
(de)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
|
AU2003231740A1
(en)
|
2002-04-19 |
2003-11-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health |
Compositions and methods for diagnostics and therapeutics for hydrocephalus
|
US20040171034A1
(en)
*
|
2002-05-03 |
2004-09-02 |
Brian Agnew |
Compositions and methods for detection and isolation of phosphorylated molecules
|
US7445894B2
(en)
*
|
2002-05-03 |
2008-11-04 |
Molecular Probes, Inc. |
Compositions and methods for detection and isolation of phosphorylated molecules
|
CN1665790A
(zh)
*
|
2002-05-03 |
2005-09-07 |
莫莱丘莱尔探针公司 |
用于检测和分离磷酸化分子的组合物及方法
|
EP2305710A3
(de)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetische Antikörperphagenbibliotheken
|
JP2005528905A
(ja)
|
2002-06-07 |
2005-09-29 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
EP2383278A1
(de)
|
2002-07-08 |
2011-11-02 |
Genentech, Inc. |
Methodenbestimmung zu B-Zell-vermittelten Krankheiten
|
JP5401001B2
(ja)
|
2002-09-11 |
2014-01-29 |
ジェネンテック, インコーポレイテッド |
免疫関連疾患の治療のための新規組成物と方法
|
WO2004024072A2
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
CA2497661A1
(en)
|
2002-09-11 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro71061
|
EP2444409A2
(de)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
|
US7179645B2
(en)
*
|
2002-09-24 |
2007-02-20 |
Antigen Express, Inc. |
Ii-Key/antigenic epitope hybrid peptide vaccines
|
AU2003294220A1
(en)
|
2002-09-17 |
2004-04-23 |
Antigen Express, Inc. |
Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
|
US20070042945A1
(en)
|
2002-09-25 |
2007-02-22 |
Genentech, Inc. |
Nouvelles compositions et methods de traitement du psoriasis
|
AU2003301576A1
(en)
|
2002-10-22 |
2004-05-13 |
Eisai Co., Ltd. |
Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division
|
EP1576137A4
(de)
|
2002-10-29 |
2010-06-30 |
Genentech Inc |
Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
|
US20070048301A1
(en)
|
2002-11-26 |
2007-03-01 |
Bodary-Winter Sarah C |
Compositions and methods for the treatment of immune related diseases
|
EP1572227B1
(de)
|
2002-12-16 |
2012-02-15 |
DeveloGen Aktiengesellschaft |
Pik4cb involviert in der regulierung des energiestoffwechsels
|
GB0300718D0
(en)
|
2003-01-13 |
2003-02-12 |
Ares Trading Sa |
Proteins
|
CA2513985C
(en)
*
|
2003-01-21 |
2012-05-29 |
Illumina Inc. |
Chemical reaction monitor
|
US6910785B2
(en)
*
|
2003-01-22 |
2005-06-28 |
Cooper Technologies Company |
Industrial luminaire with prismatic refractor
|
EP1452868A2
(de)
|
2003-02-27 |
2004-09-01 |
Pepscan Systems B.V. |
Verfahren zur Selektion eines potenziellen Arzneimittels
|
US20040185499A1
(en)
*
|
2003-03-20 |
2004-09-23 |
Jolley Michael E. |
Method of epitope scanning using fluorescence polarization
|
AU2003901425A0
(en)
|
2003-03-27 |
2003-04-10 |
Bionomics Limited |
A diagnostic method for epilepsy
|
AU2003901511A0
(en)
|
2003-03-28 |
2003-04-17 |
Bionomics Limited |
Nucleic acid molecules associated with angiogenesis II
|
CA2521940C
(en)
|
2003-04-23 |
2010-01-26 |
Latrobe University |
Insect chymotrypsin and inhibitors thereof
|
WO2004098539A2
(en)
|
2003-04-30 |
2004-11-18 |
Incyte Corporation |
Kinases and phosphatases
|
US7173010B2
(en)
|
2003-05-19 |
2007-02-06 |
Regents Of The University Of Michigan |
Orphanin FQ receptor
|
CN1816565A
(zh)
|
2003-05-21 |
2006-08-09 |
阿雷斯贸易股份有限公司 |
Tnf-样分泌性蛋白质
|
PL2784084T3
(pl)
|
2003-07-08 |
2020-03-31 |
Genentech, Inc. |
Przeciwciała antagonistyczne wobec heterologicznych polipeptydów IL-17A/F
|
EP1644406B1
(de)
|
2003-07-11 |
2012-08-15 |
DeveloGen Aktiengesellschaft |
Verwendung von dg153 sekretierter proteinprodukte zur prevention und behandlung von pankreaserkrankungen und/oder fettleibigkeit und/oder metabolischem syndrom
|
US8501473B2
(en)
|
2003-07-16 |
2013-08-06 |
Evotec International Gmbh |
Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
AU2004203373A1
(en)
|
2003-07-25 |
2005-02-10 |
University Of Chicago |
Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
PT1678194E
(pt)
|
2003-10-10 |
2013-09-30 |
Alchemia Oncology Pty Ltd |
Modulação da síntese e degradação de hialuronano no tratamento de doença
|
US20050095648A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Mario Geysen |
Method for designing linear epitopes and algorithm therefor and polypeptide epitopes
|
WO2005047478A2
(en)
|
2003-11-12 |
2005-05-26 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for regulation of tumor necrosis factor-alpha
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
US20070107073A1
(en)
|
2003-11-19 |
2007-05-10 |
Develogen Aktiengesellschaft |
Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
WO2005079840A2
(en)
|
2004-02-20 |
2005-09-01 |
Develogen Aktiengesellschaft |
Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
|
GB0403864D0
(en)
|
2004-02-20 |
2004-03-24 |
Ucl Ventures |
Modulator
|
EP1745292A2
(de)
|
2004-04-28 |
2007-01-24 |
Bayer HealthCare AG |
Diagnositka und therapeutika für mit dipeptidyl-peptidase 1 (dpp1) assoziierten krankheiten
|
NZ550366A
(en)
|
2004-05-27 |
2009-11-27 |
Crucell Holland Bv |
Binding molecules capable of neutralizing rabies virus and uses thereof
|
WO2006009241A1
(ja)
|
2004-07-22 |
2006-01-26 |
Eisai Co., Ltd. |
Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー
|
WO2006031322A2
(en)
|
2004-08-09 |
2006-03-23 |
Research Development Foundation |
Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
|
DK1797183T3
(da)
|
2004-09-02 |
2012-10-01 |
Univ Yale |
Regulering af onkogener med mikrornas
|
GB0426960D0
(en)
|
2004-12-08 |
2005-01-12 |
Ares Trading Sa |
TGR-3 like protein receptor
|
WO2006060871A1
(en)
|
2004-12-10 |
2006-06-15 |
The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland |
Binding partners of antibodies specific for dendritic cell antigens
|
WO2006067122A2
(en)
|
2004-12-20 |
2006-06-29 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
US9051572B2
(en)
|
2005-01-20 |
2015-06-09 |
Ryboquin Company Limited |
Modulators of Itch ubiquitinase activity
|
US7531523B2
(en)
|
2005-02-17 |
2009-05-12 |
Vertex Pharmaceuticals Incorporated |
Sodium channel protein type III alpha-subunit splice variant
|
EP2050763A3
(de)
|
2005-03-10 |
2009-07-15 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Modulation der Gefäßintegrität
|
WO2006100449A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
ES2565481T3
(es)
|
2005-03-24 |
2016-04-05 |
Thrombogenics N.V. |
Anticuerpo anti-PlGF novedoso
|
US20060246576A1
(en)
|
2005-04-06 |
2006-11-02 |
Affymetrix, Inc. |
Fluidic system and method for processing biological microarrays in personal instrumentation
|
JP5422203B2
(ja)
|
2005-04-19 |
2014-02-19 |
キングス カレッジ ロンドン |
使用
|
EP1879921B1
(de)
|
2005-05-12 |
2011-04-27 |
Crucell Holland B.V. |
Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon
|
AU2006255686A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
TW200643171A
(en)
|
2005-06-07 |
2006-12-16 |
Temasek Life Sciences Lab Ltd |
Porcine circovirus type 2 vaccines
|
US8354384B2
(en)
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
EP2407484B1
(de)
|
2005-06-24 |
2016-06-22 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutische proapoptotische BH3-ähnliche Moleküle und Verfahren zu deren Erzeugung und/oder Auswahl
|
EP1904095B1
(de)
|
2005-06-30 |
2013-05-29 |
VIB, vzw |
Behandlung von leberzirrhose und ihre komplikationen
|
CA2619577A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
CA2619736C
(en)
|
2005-08-18 |
2012-05-22 |
Eisai R & D Management Co., Ltd. |
Dopaminergic neuron proliferative progenitor cell marker msx1/2
|
EP1939288B1
(de)
|
2005-09-29 |
2012-12-19 |
Eisai R&D Management Co., Ltd. |
T-zelladhäsionsmolekül und gegen das molekül gerichteter antikörper
|
US7972813B2
(en)
|
2005-09-30 |
2011-07-05 |
Vertex Pharmaceuticals Incorporated |
Tetrodotoxin-resistant sodium channel alpha subunit
|
US20090293137A1
(en)
|
2005-11-21 |
2009-11-26 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
CN105859886A
(zh)
|
2005-12-02 |
2016-08-17 |
健泰科生物技术公司 |
牵涉与il-22和il-22r结合的抗体的组合物和方法
|
WO2007087113A2
(en)
|
2005-12-28 |
2007-08-02 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
EP1974041A2
(de)
|
2006-01-06 |
2008-10-01 |
University Of Georgia Research Foundation, Inc. |
Zystennematoden-resistente transgene pflanzen
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
HUE039085T2
(hu)
|
2006-01-20 |
2018-12-28 |
Cell Signaling Technology Inc |
Transzlokáció és mutáns ROS kináz humán nem-kissejtes tüdõ karcinómában
|
US20080311107A1
(en)
|
2006-02-17 |
2008-12-18 |
Genetech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
CA2645983A1
(en)
|
2006-03-17 |
2007-09-27 |
Mcgill University |
Identification of crmp4 as a convergent regulator of axon outgrowth inhibition
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
CA2649250A1
(en)
|
2006-04-11 |
2007-10-25 |
Eisai R & D Management Co., Ltd. |
Dopaminergic neuron progenitor cell marker 187a5
|
ES2637592T3
(es)
|
2006-04-14 |
2017-10-13 |
Cell Signaling Technology, Inc. |
Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
|
EP2082645A1
(de)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
EP2013346B1
(de)
|
2006-04-21 |
2014-11-26 |
Intervet International B.V. |
Pestivirus-spezies
|
US7723564B2
(en)
|
2006-05-10 |
2010-05-25 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for modulation of KSR1 and KSR2 interactions
|
US20080003667A1
(en)
*
|
2006-05-19 |
2008-01-03 |
Affymetrix, Inc. |
Consumable elements for use with fluid processing and detection systems
|
EP2027155B1
(de)
|
2006-06-06 |
2016-01-27 |
Crucell Holland B.V. |
Menschliche bindende moleküle mit abtötungswirkung gegen staphylokokken und ihre verwendung
|
WO2007141278A2
(en)
|
2006-06-06 |
2007-12-13 |
Crucell Holland B.V. |
Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
GB0614042D0
(en)
|
2006-07-14 |
2006-08-23 |
Amura Therapeutics Ltd |
Compounds
|
ATE543097T1
(de)
|
2006-07-27 |
2012-02-15 |
Univ Maryland |
Zellulärer rezeptor für antiproliferativen faktor
|
MX2009001281A
(es)
|
2006-08-01 |
2009-04-16 |
Univ Texas |
Identificacion de un micro-arn que activa la expresion de la cadena pesada de beta-miosina.
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
EP2450376B1
(de)
|
2006-09-07 |
2018-02-28 |
Janssen Vaccines & Prevention B.V. |
Zur Neutralisierung des Influenzavirus H5N1 fähige humane Bindungsmoleküle sowie deren Verwendungen
|
MX2009002174A
(es)
|
2006-09-07 |
2009-03-12 |
Crucell Holland Bv |
Moleculas de union humanas capaces de neutralizar el virus de la influenza h5n1 y usos de las mismas.
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
NZ590631A
(en)
|
2006-09-21 |
2011-12-22 |
Probiodrug Ag |
Novel genes related to glutaminyl cyclase
|
JPWO2008035527A1
(ja)
*
|
2006-09-21 |
2010-01-28 |
隆弘 越智 |
抗C1qモノクローナル抗体
|
EP2081596A4
(de)
|
2006-10-06 |
2010-07-21 |
Univ Utah Res Found |
Verfahren zum nachweis von augenkrankheiten und pathologischen zuständen und behandlung dafür
|
US7645616B2
(en)
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
US20080254512A1
(en)
|
2006-11-02 |
2008-10-16 |
Capon Daniel J |
Hybrid immunoglobulins with moving parts
|
US20110294782A1
(en)
|
2006-11-10 |
2011-12-01 |
Massachusetts Institute Of Technology |
Small molecule pak inhibitors
|
PT2120997T
(pt)
|
2006-12-21 |
2017-05-05 |
H Lundbeck As |
Modulação da atividade de proneurotrofinas
|
EP2913341A1
(de)
|
2006-12-22 |
2015-09-02 |
University of Utah Research Foundation |
Verfahren für den Nachweis von Augenerkrankungen und leiden sowie ihre Behandlung
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
JPWO2008111466A1
(ja)
|
2007-03-05 |
2010-06-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
遺伝子の発現量減少を指標とする抗ガン剤の作用検定方法
|
JPWO2008111464A1
(ja)
|
2007-03-05 |
2010-06-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スプライシング異常を指標とする抗ガン剤の作用検定方法
|
EP2164870B1
(de)
|
2007-06-27 |
2015-12-09 |
National University of Singapore |
Polypeptide und polynukleotide für artemin und entsprechende liganden sowie verfahren zu ihrer anwendung
|
CA2694930C
(en)
|
2007-07-31 |
2019-11-12 |
Board Of Regents, The University Of Texas System |
A micro-rna family that modulates fibrosis and uses thereof
|
AU2008304019A1
(en)
|
2007-09-25 |
2009-04-02 |
Pastoral Greenhouse Gas Research Ltd |
Phage Phi-mru polynucleotides and polypeptides and uses thereof
|
WO2009043104A1
(en)
|
2007-10-04 |
2009-04-09 |
Bionomics Limited |
Markers of endothelial cells and uses thereof
|
DK2203558T3
(en)
|
2007-10-18 |
2016-06-27 |
Cell Signaling Technology Inc |
TRANSLOCATION AND mutant ROS kinase IN HUMAN NON-small cell lung carcinoma
|
CA2705007A1
(en)
|
2007-11-07 |
2009-05-14 |
Genentech, Inc. |
Compositions and methods for treatment of microbial disorders
|
WO2009087379A2
(en)
|
2008-01-09 |
2009-07-16 |
Amura Therapeutics Limited |
Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
|
CA2714713C
(en)
|
2008-02-19 |
2018-02-27 |
The Children's Hospital Of Philadelphia |
Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
|
GB0804702D0
(en)
|
2008-03-13 |
2008-04-16 |
Amura Therapeutics Ltd |
Compounds
|
EP2265291B1
(de)
|
2008-03-17 |
2016-10-19 |
The Board of Regents of The University of Texas System |
Identifizierung von mikro-rna bei der erhaltung und regeneration von neuromuskulären synapsen
|
EP2116618A1
(de)
|
2008-05-09 |
2009-11-11 |
Agency for Science, Technology And Research |
Diagnose und Behandlung des Kawasaki-Syndroms
|
AU2009246134B2
(en)
|
2008-05-16 |
2016-03-03 |
The Children's Hospital Of Philadelphia |
Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
|
US9182406B2
(en)
|
2008-08-04 |
2015-11-10 |
Biodesy, Inc. |
Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
|
US20110262485A1
(en)
|
2008-08-04 |
2011-10-27 |
University Of Miami |
Sting (stimulator of interferon genes), a regulator of innate immune responses
|
EP2352761B1
(de)
|
2008-10-02 |
2016-06-22 |
Vib Vzw |
Inhibierung von plgf zur behandlung von philadelphia chromosom positiver leukämie
|
CA2740900C
(en)
*
|
2008-11-03 |
2019-09-24 |
Alethia Biotherapeutics Inc. |
Antibodies that specifically block the biological activity of a tumor antigen
|
US20100135904A1
(en)
|
2008-11-07 |
2010-06-03 |
Research Development Foundation |
Compositions and methods for the inhibition of cripto / grp78 complex formation and signaling
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
KR101829469B1
(ko)
|
2008-12-04 |
2018-03-30 |
큐알엔에이, 인크. |
Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료
|
JP5923306B2
(ja)
|
2008-12-04 |
2016-05-24 |
クルナ・インコーポレーテッド |
腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療
|
EP4169951A1
(de)
|
2008-12-09 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zell-funktion
|
WO2010071610A1
(en)
|
2008-12-19 |
2010-06-24 |
Agency For Science, Technology And Research (A*Star) |
Severe chikungunya biomarkers
|
US20100310591A1
(en)
*
|
2009-01-28 |
2010-12-09 |
Robert Humphreys |
Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
|
WO2010093904A2
(en)
|
2009-02-12 |
2010-08-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
EP2396342B1
(de)
|
2009-02-12 |
2014-09-17 |
Cell Signaling Technology, Inc. |
Expression mutanter ros bei menschlichem leberkrebs
|
GB0903759D0
(en)
|
2009-03-04 |
2009-04-15 |
Medical Res Council |
Compound
|
EP2408919B1
(de)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
|
ES2627763T3
(es)
|
2009-03-17 |
2017-07-31 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
|
CA2754605C
(en)
|
2009-03-19 |
2018-04-17 |
Medical Research Council Technology |
Pyrazolopyridine compounds and their use as lrrk2 inhibitors
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療
|
EP2427554B1
(de)
|
2009-05-08 |
2016-11-16 |
CuRNA, Inc. |
Behandlung von dystrophin-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen die dmd-familie
|
NZ596032A
(en)
|
2009-05-11 |
2013-09-27 |
Crucell Holland Bv |
Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
JP2012527248A
(ja)
|
2009-05-22 |
2012-11-08 |
クルナ・インコーポレーテッド |
転写因子e3(tfe3)に対する天然アンチセンス転写物の阻害によるtfe3およびインスリン受容体基質2(irs2)関連疾患の処置
|
KR101704988B1
(ko)
|
2009-05-28 |
2017-02-08 |
큐알엔에이, 인크. |
항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
|
CA2765509C
(en)
|
2009-06-16 |
2021-08-17 |
Joseph Collard |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6059014B2
(ja)
|
2009-06-19 |
2017-01-11 |
アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティARIZONA BOARD OF REGENTS,a body corporate acting on behalf of ARIZONA STATE UNIVERSITY |
試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ
|
KR101807323B1
(ko)
|
2009-06-24 |
2017-12-08 |
큐알엔에이, 인크. |
Tnfr2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(tnfr2) 관련된 질환의 치료
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
US9409983B2
(en)
|
2009-07-23 |
2016-08-09 |
The Board Of Trustess Of The University Of Illinois |
Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
|
CA2768947C
(en)
|
2009-07-24 |
2018-06-19 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
EP2462229B1
(de)
|
2009-08-05 |
2016-05-11 |
CuRNA, Inc. |
Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
|
CN102625841A
(zh)
|
2009-08-11 |
2012-08-01 |
欧科库尔纳有限责任公司 |
通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
|
US8791087B2
(en)
|
2009-08-21 |
2014-07-29 |
Curna, Inc. |
Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
|
GB0914767D0
(en)
|
2009-08-24 |
2009-09-30 |
Sterix Ltd |
Compound
|
CA2771172C
(en)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
BR112012004308A2
(pt)
|
2009-08-27 |
2015-09-01 |
Pastoral Greenhouse Gas Res Ltd |
Sequência do genoma completo do metanógeno methanobrevibacter ruminantium
|
GB0915332D0
(en)
|
2009-09-02 |
2009-10-07 |
Univ Leuven Kath |
New methods for diagnosing autoimmune diseases
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
JP6175236B2
(ja)
|
2009-09-25 |
2017-08-09 |
カッパーアールエヌエー,インコーポレイテッド |
フィラグリン(flg)の発現および活性の調整によるflg関連疾患の処置
|
WO2011041790A1
(en)
|
2009-10-02 |
2011-04-07 |
The Trustees Of Columbia University In The City Of New York |
Piscine reovirus diagnostic compositions
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
WO2011054359A2
(en)
|
2009-11-06 |
2011-05-12 |
University Of Copenhagen |
Method for early detection of cancer
|
CA2779437A1
(en)
|
2009-11-09 |
2011-05-12 |
Genepod Therapeutics Ab |
Novel viral vector construct for neuron specific continuous dopa synthesis in vivo
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
CN102869776B
(zh)
|
2009-12-23 |
2017-06-23 |
库尔纳公司 |
通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
|
US8962585B2
(en)
|
2009-12-29 |
2015-02-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
WO2011090740A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
KR101853511B1
(ko)
|
2009-12-31 |
2018-06-20 |
큐알엔에이, 인크. |
인슐린 수용체 기질 2 및 전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의한 irs2 관련된 질환의 치료
|
KR101878501B1
(ko)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료
|
KR101853509B1
(ko)
|
2010-01-06 |
2018-04-30 |
큐알엔에이, 인크. |
췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
|
CA2786535C
(en)
|
2010-01-11 |
2019-03-26 |
Curna, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療
|
RU2587619C2
(ru)
|
2010-02-18 |
2016-06-20 |
Дженентек, Инк. |
Антагонисты неурегулина и применение их в лечении злокачественного новообразования
|
GB201002911D0
(en)
|
2010-02-19 |
2010-04-07 |
Medical Res Council |
Compound
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
GB201004850D0
(en)
|
2010-03-23 |
2010-05-05 |
Natural Environment Res Council |
Proteins
|
US8980856B2
(en)
|
2010-04-02 |
2015-03-17 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
|
EP2374816B1
(de)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Bindemoleküle gegen Chikungunya-Virus und Verwendungen davon
|
US9441032B2
(en)
|
2010-04-07 |
2016-09-13 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
WO2011127337A2
(en)
|
2010-04-09 |
2011-10-13 |
Opko Curna Llc |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
CA2798218A1
(en)
|
2010-05-03 |
2011-11-10 |
Curna, Inc. |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
GB201008134D0
(en)
|
2010-05-14 |
2010-06-30 |
Medical Res Council Technology |
Compounds
|
EP2576783B1
(de)
|
2010-05-26 |
2017-11-29 |
CuRNA, Inc. |
Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
|
JP5917497B2
(ja)
|
2010-05-26 |
2016-05-18 |
カッパーアールエヌエー,インコーポレイテッド |
メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療
|
CN103025873B
(zh)
|
2010-06-23 |
2018-05-08 |
库尔纳公司 |
通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
WO2012019132A2
(en)
|
2010-08-06 |
2012-02-09 |
Cell Signaling Technology, Inc. |
Anaplastic lymphoma kinase in kidney cancer
|
RU2624048C2
(ru)
|
2010-10-06 |
2017-06-30 |
Курна, Инк. |
Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
|
WO2012051306A2
(en)
|
2010-10-12 |
2012-04-19 |
Gencia Corporation |
Compositions and methods for modulating mitochondrial proteases
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
EP2658568A1
(de)
|
2010-12-29 |
2013-11-06 |
Intervet International B.V. |
Impfstoffantigen von babesiose des hundes
|
GB201104669D0
(en)
|
2011-03-18 |
2011-05-04 |
Medical Res Council Technology |
Compound
|
US9428789B2
(en)
|
2011-03-21 |
2016-08-30 |
Biodesy, Inc. |
Classification of kinase inhibitors using nonlinear optical techniques
|
US10352936B2
(en)
|
2011-04-14 |
2019-07-16 |
Apoplogic Pharmaceuticals, Inc. |
Use of tumor Fas expression to determine response to anti-cancer therapy
|
US9139824B2
(en)
|
2011-04-21 |
2015-09-22 |
The University Court Of The University Of Aberdeen |
Sapolegina protein in for use as a medicament
|
US8975293B2
(en)
|
2011-05-26 |
2015-03-10 |
Regents Of The University Of Michigan |
Epigenetic co-repressors of the gamma-globin gene and methods of using same
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
RU2620980C2
(ru)
|
2011-06-09 |
2017-05-30 |
Курна, Инк. |
Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
|
MX346206B
(es)
|
2011-07-14 |
2017-03-09 |
Crucell Holland Bv |
Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b.
|
KR20190133790A
(ko)
|
2011-08-01 |
2019-12-03 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
|
EA029151B1
(ru)
|
2011-09-06 |
2018-02-28 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
|
US10040853B2
(en)
|
2011-09-09 |
2018-08-07 |
Fred Hutchinson Cancer Research Center |
Methods and compositions involving NKG2D inhibitors and cancer
|
MX2014003094A
(es)
|
2011-09-15 |
2014-04-25 |
Genentech Inc |
Metodos para promover diferenciacion.
|
CA2849267A1
(en)
|
2011-09-20 |
2013-03-28 |
The University Of North Carolina At Chapel Hill |
Regulation of sodium channels by plunc proteins
|
CN103958668A
(zh)
|
2011-09-23 |
2014-07-30 |
路易斯维尔大学研究基金会公司 |
用于扩充细胞及改善嫁接的方法和组合物
|
EP3461839A1
(de)
|
2011-10-14 |
2019-04-03 |
F. Hoffmann-La Roche AG |
Anti-htra1-antikörper und verfahren zur verwendung
|
EP2766000A2
(de)
|
2011-10-15 |
2014-08-20 |
F.Hoffmann-La Roche Ag |
Scd1-antagonisten zur behandlung von krebs
|
PL396675A1
(pl)
|
2011-10-17 |
2013-04-29 |
Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Pan |
Gen Grainyhead-like 1 i czynnik transkrypcyjny Grainyhead-like 1 do zastosowania w regulowaniu cisnienia krwi u ssaków
|
WO2013059884A1
(en)
|
2011-10-28 |
2013-05-02 |
Itek Ventures Pty Ltd |
A gene and mutations thereof associated with seizure and movement disorders
|
JP2015501639A
(ja)
|
2011-11-23 |
2015-01-19 |
アイジェニカ バイオセラピューティクス インコーポレイテッド |
抗cd98抗体およびその使用方法
|
EP2785739B1
(de)
|
2011-12-01 |
2017-03-15 |
ThromboGenics N.V. |
Verbesserung eines augendrucksenkungsergebnisses
|
EP2804630B1
(de)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Verfahren zur verwendung von fgf19-modulatoren
|
AR089868A1
(es)
|
2012-02-03 |
2014-09-24 |
Animal Health Inst |
Vacuna vectorial de eimeria para campylobacter jejuni
|
KR102148303B1
(ko)
|
2012-02-11 |
2020-08-26 |
제넨테크, 인크. |
R-스폰딘 전위 및 그의 사용 방법
|
US9708411B2
(en)
|
2012-02-16 |
2017-07-18 |
The Penn Research Foundation |
Modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof
|
SG11201405226TA
(en)
|
2012-03-08 |
2014-11-27 |
Crucell Holland Bv |
Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
|
WO2013138374A2
(en)
|
2012-03-15 |
2013-09-19 |
Curna, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
MX2014010943A
(es)
|
2012-03-16 |
2014-11-26 |
Genentech Inc |
Proteinas estabilizadas conformacionalmente de ingenieria.
|
KR20140135198A
(ko)
|
2012-03-16 |
2014-11-25 |
에프. 호프만-라 로슈 아게 |
Pak1 억제제로 흑색종을 치료하는 방법
|
US9139863B2
(en)
|
2012-03-16 |
2015-09-22 |
Genentech, Inc. |
Engineered conformationally-stabilized proteins
|
GB201204985D0
(en)
|
2012-03-21 |
2012-05-02 |
Genentech Inc |
Compounds
|
PL2838998T3
(pl)
|
2012-04-18 |
2018-04-30 |
Cell Signaling Technology, Inc. |
EGFR i ROS1 w nowotworze
|
JP6302460B2
(ja)
|
2012-04-25 |
2018-03-28 |
バイオデシー, インコーポレイテッド |
タンパク質のアロステリックモジュレーターを検出するための方法
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
CA2874144C
(en)
|
2012-05-31 |
2023-12-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
KR20150070181A
(ko)
|
2012-09-27 |
2015-06-24 |
크루셀 홀란드 비.브이. |
B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
GB201220843D0
(en)
|
2012-11-20 |
2013-01-02 |
Univ College Cork Nat Univ Ie |
Compound
|
BR112015017903A2
(pt)
|
2013-01-28 |
2017-11-21 |
Univ Danmarks Tekniske |
vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
CA2905070A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
CN110079599B
(zh)
|
2013-03-15 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
治疗pd-1和pd-l1相关疾患的生物标志物和方法
|
SG11201507429TA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
US20160143910A1
(en)
|
2013-03-15 |
2016-05-26 |
Constellation Pharmaceuticals, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
JP6715766B2
(ja)
|
2013-06-21 |
2020-07-01 |
ザ ジョンズ ホプキンス ユニバーシティ |
ヒト膜蛋白質の機能および相互作用をプロファイリングするためのビリオンディスプレイアレイ
|
TWI685349B
(zh)
|
2013-07-16 |
2020-02-21 |
建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
SG11201606018UA
(en)
|
2014-01-24 |
2016-08-30 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
WO2015166036A1
(en)
|
2014-05-02 |
2015-11-05 |
Morphosys Ag |
Peptide libraries
|
EP3636073B1
(de)
|
2014-05-05 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Humanisierte c5- und c3-tiere
|
EP3146071B1
(de)
|
2014-05-23 |
2020-09-02 |
F. Hoffmann-La Roche AG |
Mit-biomarker und verfahren mit verwendung davon
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
JP6621815B2
(ja)
|
2014-07-02 |
2019-12-18 |
インフレクティス・バイオサイエンス |
O−アルキル−ベンジリデングアニジン誘導体、及びミスフォールドタンパク質の蓄積と関連する障害の処置のための治療的使用
|
CA2951191C
(en)
|
2014-07-02 |
2022-09-13 |
Inflectis Bioscience |
Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
|
AR101210A1
(es)
|
2014-07-15 |
2016-11-30 |
Genentech Inc |
Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
|
WO2016037157A2
(en)
|
2014-09-05 |
2016-03-10 |
The Johns Hopkins University |
Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
|
EP3212811B1
(de)
|
2014-10-29 |
2020-09-09 |
The Children's Hospital of Philadelphia |
Diagnose von genetischen veränderungen im zusammenhang mit eosinophiler ösophagitis
|
PL3789402T3
(pl)
|
2014-11-20 |
2022-10-17 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona składająca się z dwuswoistych cząsteczek wiążących antygen aktywujących limfocyty T oraz antagonistów wiązania osi PD-1
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
EP3237906B8
(de)
|
2014-12-23 |
2020-10-28 |
Bluelight Therapeutics, Inc. |
Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
|
WO2016124682A1
(en)
|
2015-02-05 |
2016-08-11 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza neuraminidase
|
SG11201705614QA
(en)
|
2015-02-05 |
2017-08-30 |
Janssen Vaccines & Prevention Bv |
Binding molecules directed against influenza hemagglutinin and uses thereof
|
CA2981068C
(en)
|
2015-03-26 |
2021-12-14 |
Women & Infants Hospital Of Rhode Island |
Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
|
GB201508747D0
(en)
|
2015-05-21 |
2015-07-01 |
Univ Edinburgh |
Compounds
|
CA3176224A1
(en)
|
2015-05-22 |
2016-12-01 |
Translational Drug Development Llc |
Benzamide and active compound compositions and methods of use
|
US20180188257A1
(en)
|
2015-06-19 |
2018-07-05 |
University Of Rochester |
Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
|
JP2018523488A
(ja)
|
2015-08-21 |
2018-08-23 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia |
自己免疫疾患の治療及び診断のために組み合わせて使用するための組成物及び方法
|
US10758886B2
(en)
|
2015-09-14 |
2020-09-01 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Conditioned surfaces for in situ molecular array synthesis
|
EP3355902B1
(de)
|
2015-09-30 |
2022-04-13 |
Merck Patent GmbH |
Kombination eines pd-1-achsen-bindungsantagonisten und eines alk-inhibitors zur behandlung von alk-negativem krebs
|
CA3001362C
(en)
|
2015-10-30 |
2020-10-13 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
WO2017079442A1
(en)
|
2015-11-04 |
2017-05-11 |
Icahn School Of Medicine At Mount Sinai |
Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
|
GB201520500D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
GB201520499D0
(en)
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
EP3405478A4
(de)
|
2015-12-23 |
2019-10-30 |
Moonshot Pharma LLC |
Verfahren zur induzierung einer immunantwort durch hemmung von nonsense-vermitteltem zerfall
|
WO2017148889A1
(en)
|
2016-03-01 |
2017-09-08 |
Janssen Vaccines & Prevention B.V. |
Human neutralizing antibodies binding to influenza b neuraminidase
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
CA3026844A1
(en)
|
2016-06-15 |
2017-12-21 |
Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
Substituted tricyclic heterocyclic compounds and use thereof
|
EP3472201A4
(de)
|
2016-06-20 |
2020-05-13 |
Healthtell Inc. |
Verfahren zur differentiellen diagnose von autoimmunerkrankungen
|
CN109790203A
(zh)
|
2016-06-20 |
2019-05-21 |
健康之语公司 |
自身免疫疾病的诊断和治疗方法
|
WO2018009417A1
(en)
|
2016-07-05 |
2018-01-11 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
KR20190063473A
(ko)
|
2016-09-28 |
2019-06-07 |
블레이드 테라퓨틱스, 인크. |
칼페인 조정자 및 그 치료학적 용도
|
WO2018089858A1
(en)
|
2016-11-11 |
2018-05-17 |
Healthtell Inc. |
Methods for identifying candidate biomarkers
|
EP3544601B1
(de)
|
2016-11-23 |
2024-03-20 |
Translational Drug Development, LLC |
Eine zusammensetzung, die ein benzamid und einen tnfrsf-agonisten umfasst, der an 4-1bb oder gitr bindet, und die verwendung derselben bei der behandlung von krebs.
|
GB201622365D0
(en)
|
2016-12-29 |
2017-02-15 |
Medical Res Council Tech |
Compounds
|
GB201622362D0
(en)
|
2016-12-29 |
2017-02-15 |
Medical Res Council Tech |
Compounds
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
CA3054167A1
(en)
|
2017-02-27 |
2018-08-30 |
Regeneron Pharmaceuticals, Inc. |
Humanized model of kidney and liver disorders
|
US11771703B2
(en)
|
2017-03-17 |
2023-10-03 |
The Johns Hopkins University |
Targeted epigenetic therapy against distal regulatory element of TGFβ2 expression
|
CA3059615A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
US11654135B2
(en)
|
2017-06-22 |
2023-05-23 |
Moonshot Pharma Llc |
Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
|
EP3652209A2
(de)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonistische antikörper zur bindung von humanem cd137 und verwendungen davon
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
EP3675880B1
(de)
|
2017-09-01 |
2023-06-07 |
The Johns Hopkins University |
Gezielte epigenetische therapie für vererbte aortenaneurysmen
|
WO2019055618A1
(en)
|
2017-09-15 |
2019-03-21 |
Arizona Board Of Regents On Behalf Of Arizona State University |
METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
SG11202107538VA
(en)
|
2019-01-16 |
2021-08-30 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
WO2020159445A1
(en)
|
2019-01-31 |
2020-08-06 |
Agency For Science, Technology And Research |
Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
|
US20220241412A1
(en)
|
2019-05-24 |
2022-08-04 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
EP4038222A4
(de)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
BR112022008142A2
(pt)
|
2019-11-20 |
2022-08-23 |
Intervet Int Bv |
Nova vacina contra heamophilus parasuis
|
BR112022009507A2
(pt)
|
2019-11-20 |
2022-08-16 |
Intervet Int Bv |
Uma nova vacina contra heamophilus parasuis
|
WO2021099446A1
(en)
|
2019-11-20 |
2021-05-27 |
Intervet International B.V. |
A novel vaccine against heamophilus parasuis
|
CA3190782A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
|
CA3197034A1
(en)
|
2020-10-29 |
2022-05-05 |
Suzhou Yabao Pharmaceutical R&D Co., Ltd. |
Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
|
WO2022118197A1
(en)
|
2020-12-02 |
2022-06-09 |
Pfizer Inc. |
Time to resolution of axitinib-related adverse events
|
BR112023025738A2
(pt)
|
2021-06-09 |
2024-02-27 |
Hoffmann La Roche |
Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
WO2023057882A1
(en)
|
2021-10-05 |
2023-04-13 |
Pfizer Inc. |
Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
|